loading page

A Clinician Survey of Use Assessment, Documentation, and Education about Cannabis Use in Persons with Cystic Fibrosis
  • +4
  • Corinne Muirhead,
  • Wendy Palmrose,
  • Michelle Condren,
  • Shannon Rotolo,
  • Rebecca Pettit,
  • Mohsain Gill,
  • Hanna Phan
Corinne Muirhead
Oregon Health & Science University Hospital
Author Profile
Wendy Palmrose
Oregon Health & Science University Hospital
Author Profile
Michelle Condren
University of Oklahoma
Author Profile
Shannon Rotolo
UChicago Medicine
Author Profile
Rebecca Pettit
Riley Hospital for Children at Indiana University Health
Author Profile
Mohsain Gill
The University of Oklahoma College of Medicine
Author Profile
Hanna Phan
University of Michigan
Author Profile


Introduction: To help open the clinician dialogue regarding cannabis use in persons with CF in the U.S., we aimed to describe current practices of use assessment and documentation processes related to cannabis. Methods: A cross sectional, anonymous survey study was distributed via email to CF directors and coordinators and to the Cystic Fibrosis Foundation (CFF) listservs of nurse, pharmacist, dietitian, social worker and psychology care team members. The survey tool included multiple choice, scaled and open ended items, which assessed participants’ awareness of current cannabis laws in their state, prescribing practices for medical marijuana, screening and documentation practices, knowledge of and what indications participants believe cannabis and cannabidiol (CBD) could be beneficial. Data was analyzed using descriptive statistics. Results: There were 282 survey participants, with majority as providers (28%) and social workers (29%), representing all U.S. regions. Participants varied in terms of frequency of evaluating cannabis use, with 15.4% “always,” 48.4% “sometimes,” and 41% “rarely” or “never” asking about it. Regarding recreational versus medical cannabis use, 55.4% and 62.5% reported documentation of each type in the medical record, respectively. Participants reported appetite, pain, and nausea as the top three advocated indications for use. About 35% and 72% of participants felt “slightly” or “not at all” prepared to answer patient/family questions about cannabis and CBD, respectively. Conclusions: The approach to cannabis use assessment, documentation, and education across CF care centers is variable. There is a need for care team and patient/caregiver education materials about cannabis/CBD and CF.

Peer review status:ACCEPTED

28 Feb 2021Submitted to Pediatric Pulmonology
01 Mar 2021Submission Checks Completed
01 Mar 2021Assigned to Editor
01 Mar 2021Reviewer(s) Assigned
17 Mar 2021Review(s) Completed, Editorial Evaluation Pending
22 Mar 2021Editorial Decision: Revise Minor
16 Apr 20211st Revision Received
20 Apr 2021Submission Checks Completed
20 Apr 2021Assigned to Editor
20 Apr 2021Reviewer(s) Assigned
07 Jun 2021Review(s) Completed, Editorial Evaluation Pending
21 Jun 2021Editorial Decision: Revise Minor
21 Jun 20212nd Revision Received
22 Jun 2021Submission Checks Completed
22 Jun 2021Assigned to Editor
22 Jun 2021Reviewer(s) Assigned
29 Jun 2021Review(s) Completed, Editorial Evaluation Pending
01 Jul 2021Editorial Decision: Accept